Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1995 Dec;86(12):1203–1209. doi: 10.1111/j.1349-7006.1995.tb03316.x

Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities

Tomohide Tamura 1,✉, Yasutsuna Sasaki 3, Yutaka Nishiwaki 4, Nagahiro Saijo 1,2
PMCID: PMC5920663  PMID: 8636011

Abstract

The primary objectives of this study were to determine the maximum tolerated dose (MTD) of paclitaxel administered by 3‐h infusion to patients with solid tumors, and to characterize the pharmacokinetics of a 3‐h infusion in comparison with those of a 24‐h infusion. Twenty‐seven patients each received one of six levels of paclitaxel, 105, 135, 180, 210, 240 and 270 mg/m2, with premedication. Two patients given 240 mg/m2 and one patient given 270 mg/m2 unexpectedly had grade 3/4 hypotension just after finishing the paclitaxel infusion. Peripheral neuropathy was also dose‐limiting at 270 mg/m2. Although granulocytopenia was significantly less severe than with a 24‐h infusion, more than half of the patients experienced grade 4 toxicity at doses of 240 or 270 mg/m2. Severe hypersensitivity reactions (HSRs) were not observed. Pharmacokinetic studies using high performance liquid chromatography demonstrated proportionally greater increases in the peak plasma concentration and area under the curve, and decreases in clearance and volume of distribution with increasing dose, suggesting non‐linear pharmacokinetics of paclitaxel when given by 3‐h infusion. The MTD of paclitaxel given as a 3‐h infusion was determined to be 240 mg/m2 with dose‐limiting toxicities of granulocytopenia, peripheral neuropathy and hypotension. Hypotension just after infusion, induced by 3‐h infusion of paclitaxel, is a new observation which has not been reported previously. The recommended dose for phase II study is 210 mg/m2. Although hypotension was observed as an unexpected toxic effect, paclitaxel could be administered safely over 3 h with premedication and proper monitoring, resulting in reduced myelotoxicity and with no increase in the incidence of HSRs as compared with a 24‐h infusion.

Keywords: Paclitaxel, Phase I study, Non‐linear pharmacokinetics

Full Text

The Full Text of this article is available as a PDF (435.8 KB).

REFERENCES

  • 1. ) Wani , M. C. , Taylor , H. L. , Wall , M. E. , Coggon , P. and McPhail , A. T.Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia . J. Am. Chem. Soc. , 93 , 2325 – 2327 ( 1971. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) National Cancer Institute. “Clinical Brochure: Taxol (NSC 125973) ,” pp. 6 – 12 ( 1983. ). Division of Cancer Treatment , NCI; , Bethesda , MD . [Google Scholar]
  • 3. ) Schiff , P. B. , Fant , J. and Horwitz , S. B.Promotion of microtubule assembly in vitro by taxol . Nature , 277 , 665 – 667 ( 1979. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Schiff , P. B. and Horwitz , S. B.Taxol stabilizes micro‐tubules in mouse fibroblast cells . Proc. Natl. Acad. Sci. USA , 77 , 1561 – 1565 ( 1980. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. ) Rowinsky , E. K. , Cazenave , L. A. and Donehower , R. C.Taxol: a novel investigational antimicrotubule agent . J. Natl. Cancer Inst. , 82 , 1247 – 1259 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Weiss , R. B. , Donehower , R. C. , Wiernik , P. H. , Ohnuma , T. , Oralla , R. J. , Trump , D. L. , Baker , J. R. , Jr. , Van Echo , D. A. , Von Hoff , D. D. and Leyland‐Jones , B.Hypersensitivity reactions from taxol . J. clin. Oncol. , 8 , 1263 – 1268 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Lorenz , W. , Reimann , H. I. , Schmal , A. , Dormann , P. , Schwarz , B. , Neugebauer , E. and Doenicke , A.Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent . Agents Actions , 7 , 63 – 67 ( 1977. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) McGuire , W. P. , Rowinsky , E. K. , Rosenshein , N. B. , Orumbine , F. C. , Ettinger , D. S. , Armstrong , D. K. and Donehower , R. C.Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms . Ann. Intern. Med. , 111 , 273 – 279 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Holmes , F. A. , Walters , R. S. , Theriault , R. L. , Forman , A. D. , Newton , L. K. , Raber , M. N. , Buzdar , A. U. , Frye , D. K. and Hortobagyi , G. N.Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer . J. Natl Cancer Inst. , 83 , 1797 – 1805 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Chang , A. Y. , Kim , K. , Glick , J. , Anderson , T. , Karp , D. and Johnson , D.Phase II study of taxol, merbarone, and piroxantrone in stage IV non‐small‐cell lung cancer: the Eastern Cooperative Oncology Group results . J. Natl. Cancer Inst. , 85 , 388 – 394 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Murphy , W. K. , Fossella , F. V. , Winn , R. J. , Shin , D. M. , Hynes , H. E. , Gross , H. M. , Davilla , E. , Leimert , J. , Dhingra , H. , Raber , M. N. , Krakoff , I. H. and Hong , W. K.Phase II study of taxol in patients with untreated advanced non‐small‐cell lung cancer . J. Natl. Cancer Inst. , 85 , 384 – 388 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Tamura , T. , Sasaki , Y. , Eguchi , K. , Shinkai , T. , Ohe , Y. , Nishio , M. , Kunikane , H. , Arioka , H. , Karato , A. , Omatsu , H. , Nakashima , H. and Saijo , N.Phase I and pharmacokinetic study of paclitaxel by 24‐hour intravenous infusion . Jpn. J. Cancer Res. , 85 , 1057 – 1062 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. ) Eisenhauer , E. A. , ten Bokkel Huinink , W. W. , Swenerton , K. D. , Gianni , L. , Myles , J. , van der Burg , M. E. L. , Kerr , I. , Vermorken , J. B. , Buser , K. , Colombo , N. , Bacon , M. , Santabarbara , P. , Onetto , N. , Winograd , B. and Canetta , R.European‐Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high‐dose versus low‐dose and long versus short infusion . J. Clin. Oncol , 12 , 2654 – 2666 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Zubrod , G. C. , Scheideman , M. , Frei , E. , III , Brindley , C , Gold , L. G. , Schnider , B. , Oviedo , R. , Gorman , J. , Jones , R. , Jr. , Johnson , U. , Colsky , J. , Chalmers , T. , Ferguson , B. , Derick , M. , Holland , J. , Selawry , O. , Regelson , W. , Lasagna , C. and Owens , A. HAppraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thio‐phosphoramide . J. Chronic Dis. , 11 , 7 – 33 ( 1960. ). [Google Scholar]
  • 15. ) Collins , J. M. , Zaharko , D. S. , Dedrick , R. L. and Chabner , B. A.Potential roles for preclinical pharmacology in phase I clinical trials . Cancer Treat. Rep. , 70 , 73 – 80 ( 1986. ). [PubMed] [Google Scholar]
  • 16. ) Oken , M. M. , Creech , R. H. , Tormey , D. C , Horton , J. , Davis , T. E. , McFadden , E. T. and Carbone , P. P.Toxic‐ity and response criteria of the Eastern Cooperative Oncology Group . Am. J. Clin. Oncol , 5 , 649 – 655 ( 1982. ). [PubMed] [Google Scholar]
  • 17. ) Grem , J. L. , Tutsch , K. D. , Simon , K. J. , Alberti , D. B. , Willson , J. K. V. , Tormey , D. C. , Swaminathan , S. and Trump , D. L.Phase I study of taxol administered as a short iv infusion daily for 5 days . Cancer Treat. Rep. , 71 , 1179 – 1184 ( 1987. ). [PubMed] [Google Scholar]
  • 18. ) Sonnichsen , D. S. , Hurwitz , C. A. , Pratt , C. B. , Shuster , J. J. and Relling , M. V.Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors . J. Clin. Oncol. , 12 , 532 – 538 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Gianni , L. , Kearns , C. M. , Giani , A. , Capri , G. , Vigano , L. , Locatelli , A. , Bonadonna , G. and Egorin , M. J.Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J . Clin. Oncol. , 13 , 180 – 190 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Schiller , J. H. , Storer , B. , Tutsch , K. , Arzoomanian , R. , Alberti , D. , Feierabend , C. and Spriggs , D.Phase I trial of 3‐hour infusion of paclitaxel with or without granulocyte colony‐stimulating factor in patients with advanced cancer . J Clin. Oncol. , 12 , 241 – 248 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Onetto , N. , Canetta , R. , Winograd , B. , Catane , R. , Dougan , M. , Grechko , J. , Burroughs , J. and Rozencweig , M.Overview of taxol safety . J. Natl. Cancer Inst. Monogr. , 15 , 131 – 139 ( 1993. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES